TSHR and breast carcinoma: Consequently, neutral TSHR antagonists (ligands inhibiting receptor activation by agonists), such as NIDDK-CEB-52, NCGC00242595 and NCGC00229600, could play a potential role in the breast cancer prophylaxis, acting as precursors of drugs preventing from TSHRAb activation in patients with Graves’ disease [45].